Results 221 to 230 of about 425,528 (280)

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic, Sajeve S. Thomas, William R. Robinson III, Hye Sung Kim, Liam Il‐Young Chung, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock   +16 more
wiley   +1 more source

Rare metastasis of renal cell carcinoma to the breast: a case report. [PDF]

Oxf Med Case Reports
Sahoo AS, Singh B, Salman M, Ragad L, Elayyan R.   +4 more
europepmc   +1 more source

Immunosuppressive JAG2+ tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells

Cancer Communications, EarlyView.
Abstract Background Tumor‐associated neutrophils (TANs) play a critical role in modulating immune responses and exhibit significant heterogeneity. Our previous study demonstrated that jagged canonical Notch ligand 2 (JAG2)+ TANs were associated with an immunosuppressive microenvironment in high‐grade serous ovarian cancer (HGSOC), but the underlying ...
Chenyang Wang, Moran Yang, Yujing Zhong, Kankan Cao, Xueling Wang, Chen Zhang, Yiying Wang, Mengdi He, Jiaqi Lu, Guodong Zhang, Yan Huang, Haiou Liu   +11 more
wiley   +1 more source

Cases - Renal cell carcinoma with remote testicular metastases. [PDF]

Can Urol Assoc J
Sidhom K, Morra M, Kuzyk N, Kalikias S, Zhang H, Nayak J, Ahmad AE.   +6 more
europepmc   +1 more source

Combating cancer immunotherapy resistance: a nano‐medicine perspective

Cancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong, Xintong Xie, Juan Wu, Xiangyu Wang, Wenxiang Zhang, Shuowen Wang, Daria Valerievna Abbasova, Yi Fang, Hongnan Jiang, Jidong Gao, Jing Wang   +10 more
wiley   +1 more source

Chrysoeriol Chemosensitized Renal Cell Carcinoma (RCC) Cell Lines to Trigger TRAIL Induced Apoptosis In Vitro by Up-Regulating Pro-Apoptotic and Down-Regulating Anti-Apoptotic Genetic Factors. [PDF]

Food Sci Nutr
Batool Z, Wu Q, Kamal MA, Weng G, Shen B.   +4 more
europepmc   +1 more source

Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor

Cancer Communications, EarlyView.
Abstract Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. However, their functional importance in disease progression has often been underestimated due to their ...
Wenpeng Cai, Tao Fan, Chu Xiao, Ziqin Deng, Yixiao Liu, Chunxiang Li, Jie He   +6 more
wiley   +1 more source

Papillary renal neoplasm with reversed polarity: A case report of a rare renal tumor. [PDF]

Int J Surg Case Rep
Kannan S, Akram WM, Elmussareh M, Saleh R.   +3 more
europepmc   +1 more source

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

Cancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng, Shuang Zhang, Liang Han, Lin Wu, Jun Chen, Peiyan Zhao, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Haoyu Yu, Jing Li, Fang Yang, Xinyi Yang, Chen Ling, Qingyu Wang, Yongqiang Shan, Jun Zhu, the ASTRUM‐005 Study Group   +32 more
wiley   +1 more source

Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation. [PDF]

Discov Oncol
Yan H, Zhang L, Xu F, Chen T, Li R.
europepmc   +1 more source